189 related articles for article (PubMed ID: 30945818)
1. Structure-Based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]pyridin-2-one-Based p38 MAP Kinase Inhibitors: Part 1.
Kaieda A; Takahashi M; Fukuda H; Okamoto R; Morimoto S; Gotoh M; Miyazaki T; Hori Y; Unno S; Kawamoto T; Tanaka T; Itono S; Takagi T; Sugimoto H; Okada K; Snell G; Bertsch R; Nguyen J; Sang BC; Miwatashi S
ChemMedChem; 2019 May; 14(10):1022-1030. PubMed ID: 30945818
[TBL] [Abstract][Full Text] [Related]
2. Structure-Based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]Pyridin-2-one-Based p38 MAP Kinase Inhibitors: Part 2.
Kaieda A; Takahashi M; Fukuda H; Okamoto R; Morimoto S; Gotoh M; Miyazaki T; Hori Y; Unno S; Kawamoto T; Tanaka T; Itono S; Takagi T; Sugimoto H; Okada K; Lane W; Sang BC; Saikatendu K; Matsunaga S; Miwatashi S
ChemMedChem; 2019 Dec; 14(24):2093-2101. PubMed ID: 31697454
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine-based p38 MAP kinase inhibitors.
Kaieda A; Takahashi M; Takai T; Goto M; Miyazaki T; Hori Y; Unno S; Kawamoto T; Tanaka T; Itono S; Takagi T; Hamada T; Shirasaki M; Okada K; Snell G; Bragstad K; Sang BC; Uchikawa O; Miwatashi S
Bioorg Med Chem; 2018 Feb; 26(3):647-660. PubMed ID: 29291937
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 3H-imidazo[4,5-b]pyridines as potent c-Met kinase inhibitors: design, synthesis, and biological evaluation.
Chen D; Wang Y; Ma Y; Xiong B; Ai J; Chen Y; Geng M; Shen J
ChemMedChem; 2012 Jun; 7(6):1057-70. PubMed ID: 22581753
[TBL] [Abstract][Full Text] [Related]
5. Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase.
Selness SR; Devraj RV; Monahan JB; Boehm TL; Walker JK; Devadas B; Durley RC; Kurumbail R; Shieh H; Xing L; Hepperle M; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R
Bioorg Med Chem Lett; 2009 Oct; 19(20):5851-6. PubMed ID: 19751974
[TBL] [Abstract][Full Text] [Related]
6. BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring.
Nourry A; Zambon A; Davies L; Niculescu-Duvaz I; Dijkstra HP; Ménard D; Gaulon C; Niculescu-Duvaz D; Suijkerbuijk BM; Friedlos F; Manne HA; Kirk R; Whittaker S; Marais R; Springer CJ
J Med Chem; 2010 Mar; 53(5):1964-78. PubMed ID: 20148563
[TBL] [Abstract][Full Text] [Related]
7. Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone.
Vallée F; Carrez C; Pilorge F; Dupuy A; Parent A; Bertin L; Thompson F; Ferrari P; Fassy F; Lamberton A; Thomas A; Arrebola R; Guerif S; Rohaut A; Certal V; Ruxer JM; Gouyon T; Delorme C; Jouanen A; Dumas J; Grépin C; Combeau C; Goulaouic H; Dereu N; Mikol V; Mailliet P; Minoux H
J Med Chem; 2011 Oct; 54(20):7206-19. PubMed ID: 21972823
[TBL] [Abstract][Full Text] [Related]
8. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase.
Wilson KP; McCaffrey PG; Hsiao K; Pazhanisamy S; Galullo V; Bemis GW; Fitzgibbon MJ; Caron PR; Murcko MA; Su MS
Chem Biol; 1997 Jun; 4(6):423-31. PubMed ID: 9224565
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as novel and potent Nek2 inhibitors with in vitro and in vivo antitumor activities.
Xi JB; Fang YF; Frett B; Zhu ML; Zhu T; Kong YN; Guan FJ; Zhao Y; Zhang XW; Li HY; Ma ML; Hu W
Eur J Med Chem; 2017 Jan; 126():1083-1106. PubMed ID: 28039836
[TBL] [Abstract][Full Text] [Related]
10. Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent.
Miwatashi S; Arikawa Y; Kotani E; Miyamoto M; Naruo K; Kimura H; Tanaka T; Asahi S; Ohkawa S
J Med Chem; 2005 Sep; 48(19):5966-79. PubMed ID: 16162000
[TBL] [Abstract][Full Text] [Related]
11. Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors.
Terao Y; Suzuki H; Yoshikawa M; Yashiro H; Takekawa S; Fujitani Y; Okada K; Inoue Y; Yamamoto Y; Nakagawa H; Yao S; Kawamoto T; Uchikawa O
Bioorg Med Chem Lett; 2012 Dec; 22(24):7326-9. PubMed ID: 23147077
[TBL] [Abstract][Full Text] [Related]
12. Pyridinylquinoxalines and pyridinylpyridopyrazines as lead compounds for novel p38 alpha mitogen-activated protein kinase inhibitors.
Koch P; Jahns H; Schattel V; Goettert M; Laufer S
J Med Chem; 2010 Feb; 53(3):1128-37. PubMed ID: 20078117
[TBL] [Abstract][Full Text] [Related]
13. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
Bioorg Med Chem Lett; 2008 Mar; 18(6):1772-7. PubMed ID: 18325768
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
Liverton NJ; Butcher JW; Claiborne CF; Claremon DA; Libby BE; Nguyen KT; Pitzenberger SM; Selnick HG; Smith GR; Tebben A; Vacca JP; Varga SL; Agarwal L; Dancheck K; Forsyth AJ; Fletcher DS; Frantz B; Hanlon WA; Harper CF; Hofsess SJ; Kostura M; Lin J; Luell S; O'Neill EA; O'Keefe SJ
J Med Chem; 1999 Jun; 42(12):2180-90. PubMed ID: 10377223
[TBL] [Abstract][Full Text] [Related]
15. Insight into the structural determinants of imidazole scaffold-based derivatives as p38 MAP kinase inhibitors by computational explorations.
Huang C; Li Y; Ren H; Wang J; Shao L; Zhang S; Li G; Yang L
Curr Med Chem; 2012; 19(23):4024-37. PubMed ID: 22680637
[TBL] [Abstract][Full Text] [Related]
16. Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
Wurz RP; Pettus LH; Henkle B; Sherman L; Plant M; Miner K; McBride HJ; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
Bioorg Med Chem Lett; 2010 Mar; 20(5):1680-4. PubMed ID: 20138761
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of ML3403 ({4-[5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-Pyridinylimidazole-type p38 mitogen-activated protein kinase inhibitor.
Kammerer B; Scheible H; Albrecht W; Gleiter CH; Laufer S
Drug Metab Dispos; 2007 Jun; 35(6):875-83. PubMed ID: 17344341
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and evaluation of novel VEGFR2 kinase inhibitors: discovery of [1,2,4]triazolo[1,5-a]pyridine derivatives with slow dissociation kinetics.
Oguro Y; Cary DR; Miyamoto N; Tawada M; Iwata H; Miki H; Hori A; Imamura S
Bioorg Med Chem; 2013 Aug; 21(15):4714-29. PubMed ID: 23755884
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.
Laufer SA; Hauser DR; Domeyer DM; Kinkel K; Liedtke AJ
J Med Chem; 2008 Jul; 51(14):4122-49. PubMed ID: 18578517
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase.
Trejo A; Arzeno H; Browner M; Chanda S; Cheng S; Comer DD; Dalrymple SA; Dunten P; Lafargue J; Lovejoy B; Freire-Moar J; Lim J; Mcintosh J; Miller J; Papp E; Reuter D; Roberts R; Sanpablo F; Saunders J; Song K; Villasenor A; Warren SD; Welch M; Weller P; Whiteley PE; Zeng L; Goldstein DM
J Med Chem; 2003 Oct; 46(22):4702-13. PubMed ID: 14561090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
